APA

Levine D. S., Riff D. S., Pruitt R., Wruble L., Koval G., Sales D., Bell J. K. & Johnson L. K. (20020717). A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. : The American journal of gastroenterology.

Chicago

Levine Douglas S, Riff Dennis S, Pruitt Ronald, Wruble Lawrence, Koval George, Sales David, Bell John K and Johnson Lorin K. 20020717. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. : The American journal of gastroenterology.

Harvard

Levine D. S., Riff D. S., Pruitt R., Wruble L., Koval G., Sales D., Bell J. K. and Johnson L. K. (20020717). A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. : The American journal of gastroenterology.

MLA

Levine Douglas S, Riff Dennis S, Pruitt Ronald, Wruble Lawrence, Koval George, Sales David, Bell John K and Johnson Lorin K. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. : The American journal of gastroenterology. 20020717.